Cargando…

PB2530: DIXON-BASED R2* MRI AS AN INTEGRATION/SUBSTITUTE OF STANDARD T2/R2 IN THE EVALUATION OF IRON OVERLOAD IN THE UPPER ABDOMEN

Detalles Bibliográficos
Autores principales:	Pinto, Valeria Maria, Bacigalupo, Lorenzo, Gianesin, Barbara, Cazzato, Andrea, Quintino, Sabrina, Forni, Gian Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429474/ http://dx.doi.org/10.1097/01.HS9.0000976820.94001.65

Ejemplares similares

PB2565: TRANSFUSIONAL IRON OVERLOAD AND ASSOCIATED COMPLICATIONS IN HEMATOLOGY DISORDERS PATIENTS
por: Romanenko, Nikolay, et al.
Publicado: (2023)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL
por: Shortt, Jake, et al.
Publicado: (2023)

PB1751: RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R ALL) IN A SINGLE-CENTRE PAEDIATRIC POPULATION
por: Gomes, Guadalupe Ferreira, et al.
Publicado: (2023)

2530. TACO Tuesday as a Medical Education Tool
por: McCauley, Melanie, et al.
Publicado: (2019)

PB1929: PRELIMINARY STUDY OF EVALUATION IRON OVERLOAD MYOCARDIAL INJURY BY LOAD CT MYOCARDIAL PERFUSION IMAGING
por: Zhang, Y., et al.
Publicado: (2022)

PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
por: Hamadani, M., et al.
Publicado: (2022)

PB2170: HIGH EXPRESSION OF AP2M1 CORRELATES WITH WORSE PROGNOSIS BY REGULATING IMMUNE MICROENVIRONMENT AND DRUG RESPONSE TO R-CHOP IN DLBCL
por: Liu, X.-D., et al.
Publicado: (2022)

PB2535: TRIAL IN PROGRESS: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUSPATERCEPT TO TREAT ANEMIA IN ADULTS WITH ALPHA-THALASSEMIA
por: Viprakasit, Vip, et al.
Publicado: (2023)

PB2105: REAL WORLD EXPERIENCE WITH POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR R/R DLBCL IN 3 ACADEMIC CENTERS IN MADRID, SPAIN.
por: Corrochano, M., et al.
Publicado: (2022)

PB2323: R-ESHAP VS R-ICE AS RESCUE TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE-CENTEREXPERIENCE.
por: Pérez-Pinilla, Belén, et al.
Publicado: (2023)

PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC
por: Lee, E., et al.
Publicado: (2022)

PB2301: OPTIMAL DOSE INTENSITY OF R-CHOP FOR PATIENTS WITH DLBCL AGED 80 YEARS OR OLDER: IS THE R-MINICHOP A GOLD STANDARD?
por: Nukariya, Hironao, et al.
Publicado: (2023)

PB2498: A PHASE 1 STUDY OF WU-NK-101 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Cashen, Amanda, et al.
Publicado: (2023)

2530: Should all clinical research subjects pay the same?
por: McKinney, Bernadette
Publicado: (2018)

PB1756: INOTUZUMAB OZOGAMICIN IN THERAPY RELAPSE/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL): A SINGLE CENTER EXPERIENCE
por: Antipova, A., et al.
Publicado: (2022)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
por: chen, M., et al.
Publicado: (2022)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Hamadani, M., et al.
Publicado: (2022)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML
por: Patel, Anand, et al.
Publicado: (2023)

PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE
por: Dimitraki, E.-K., et al.
Publicado: (2022)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
por: Caballero, Juan Carlos, et al.
Publicado: (2023)

PB2134: THE ROLE OF ADDITIONAL CARBOGEN GAS MIXTURE AND NICOTINAMIDE ON R-CHOP CHEMOTHERAPY IN DLBCL PATIENTS WITH TUMOR HYPOXIA
por: Rizky, D., et al.
Publicado: (2022)

PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH
por: Sabljic, A., et al.
Publicado: (2022)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

PB2283: COVID-19 (SARS-COV-2 INFECTION) IN LYMPHOMA PATIENTS
por: Tytorenko, I., et al.
Publicado: (2022)

PB2523: DI-2-ETHYLHEXYL PHTHALATE (DEHP) INHIBITS HEMOGLOBIN S POLYMERIZATION
por: Camacho, Rodrigo Abreu, et al.
Publicado: (2023)

PB1893: CLONAL EVOLUTION WITH BCL-2 AMPLIFICATION DURING VENETOCLAX TREATMENT
por: Rodríguez-Afonso, Jorge, et al.
Publicado: (2023)

PB2244: FEATURES OF POLYCYTHEMIA VERA WITH THE JAK 2 EXON 12 MUTATION.
por: Soubortseva, Irina, et al.
Publicado: (2023)

PB2146: A PHASE 2, OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (LOTIS-9)
por: Westin, J., et al.
Publicado: (2022)

PB2139: A REAL-WORLD OUTCOME OF NEWLY DIAGNOSED PRIMARY MEDIASTINAL B-CELL LYMPHOMA TREATED WITH 6 CYCLES OF R-CHOEP-14 AND 2 CYCLES OF DHAP FOLLOWED BY AN AUTOLOGOUS STEM CELL TRANSPLANT
por: Tan Tsen Chuen, J., et al.
Publicado: (2022)

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
por: Giatra, C., et al.
Publicado: (2022)

PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY
por: Lorenz, K., et al.
Publicado: (2022)

PB2257: SARS-COV-2 VARIANTS DETECTED IN EMPLOYEES OF ONE MEDICAL CENTER
por: Biderman, B., et al.
Publicado: (2022)

PB1746: EVOLUTION OF SARS-COV-2 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
por: Guerbouj, Hamida Khémiri, et al.
Publicado: (2023)

PB2104: DOSE-DENSE CHEMOTHERAPY WITH R-CHOP-14 IN OLDER ADULTS AGED ≥80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Christofyllakis, K., et al.
Publicado: (2022)

PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.
por: Mompel, O., et al.
Publicado: (2022)

PB2362: THE EFFECT OF BODY MASS INDEX (BMI) ON THE PROGNOSIS OF DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE
por: el Filali, Imane Ait, et al.
Publicado: (2023)

PB1772: HIGH SLIT2 LEVELS ARE ASSOCIATED WITH GMP LIKE AML AND TREATMENT WITH RECOMBINANT SLIT2 INHIBITS LEUKEMOGENESIS
por: Simoes, Luise Araujo de Albuquerque, et al.
Publicado: (2023)

PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
por: Vitolo, U., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kjc3t96msr0u83oat7kl0n5g8p